Incontinentia pigmenti

	WikiDoc Resources for Incontinentia pigmenti
Articles
Most recent articles on Incontinentia pigmenti Most cited articles on Incontinentia pigmenti Review articles on Incontinentia pigmenti Articles on Incontinentia pigmenti in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Incontinentia pigmenti Images of Incontinentia pigmenti Photos of Incontinentia pigmenti Podcasts & MP3s on Incontinentia pigmenti Videos on Incontinentia pigmenti
Evidence Based Medicine
Cochrane Collaboration on Incontinentia pigmenti Bandolier on Incontinentia pigmenti TRIP on Incontinentia pigmenti
Clinical Trials
Ongoing Trials on Incontinentia pigmenti at Clinical Trials.gov Trial results on Incontinentia pigmenti Clinical Trials on Incontinentia pigmenti at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Incontinentia pigmenti NICE Guidance on Incontinentia pigmenti NHS PRODIGY Guidance FDA on Incontinentia pigmenti CDC on Incontinentia pigmenti
Books
Books on Incontinentia pigmenti
News
Incontinentia pigmenti in the news Be alerted to news on Incontinentia pigmenti News trends on Incontinentia pigmenti
Commentary
Blogs on Incontinentia pigmenti
Definitions
Definitions of Incontinentia pigmenti
Patient Resources / Community
Patient resources on Incontinentia pigmenti Discussion groups on Incontinentia pigmenti Patient Handouts on Incontinentia pigmenti Directions to Hospitals Treating Incontinentia pigmenti Risk calculators and risk factors for Incontinentia pigmenti
Healthcare Provider Resources
Symptoms of Incontinentia pigmenti Causes & Risk Factors for Incontinentia pigmenti Diagnostic studies for Incontinentia pigmenti Treatment of Incontinentia pigmenti
Continuing Medical Education (CME)
CME Programs on Incontinentia pigmenti
International
Incontinentia pigmenti en Espanol Incontinentia pigmenti en Francais
Business
Incontinentia pigmenti in the Marketplace Patents on Incontinentia pigmenti
Experimental / Informatics
List of terms related to Incontinentia pigmenti

Template:DiseaseDisorder infobox

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Overview

Incontinentia Pigmenti (IP) is a genetic disorder that affects the skin, hair, teeth, and nails. It is also known as Bloch Sulzberger syndrome, Bloch Siemens syndrome, melanoblastosis cutis and naevus pigmentosus systematicus.

Presentation

The skin lesions evolve through characteristic stages:

blistering (from birth to about four months of age),
a wart-like rash (for several months),
swirling macular hyperpigmentation (from about six months of age into adulthood), followed by
linear hypopigmentation.

Alopecia, hypodontia, abnormal tooth shape, and dystrophic nails are observed. Some patients have retinal vascular abnormalities predisposing to retinal detachment in early childhood. Cognitive delays/mental retardation are occasionally seen.

Diagnosis

The diagnosis of IP is established by clinical findings and occasionally by corroborative skin biopsy. Molecular genetic testing of the IKBKG gene (chromosomal locus Xq28) reveals disease-causing mutations in about 80% of probands. Such testing is available clinically. In addition, females with IP have skewed X-chromosome inactivation; testing for this can be used to support the diagnosis.

Physical Examination

Skin

Trunk

Incontinentia pigmenti. Adapted from Dermatology Atlas.^[1]
Incontinentia pigmenti. Adapted from Dermatology Atlas.^[1]
Incontinentia pigmenti. Adapted from Dermatology Atlas.^[1]
Incontinentia pigmenti. Adapted from Dermatology Atlas.^[1]
Incontinentia pigmenti. Adapted from Dermatology Atlas.^[1]

Extremity

Incontinentia pigmenti. Adapted from Dermatology Atlas.^[1]
Incontinentia pigmenti. Adapted from Dermatology Atlas.^[1]
Incontinentia pigmenti. Adapted from Dermatology Atlas.^[1]

Genetics

IP is inherited in an X-linked dominant manner. IP is lethal in most, but not all, males. A female with IP may have inherited the IKBKG mutation from either parent or have a new gene mutation. Parents may either be clinically affected or have germline mosaicism. Affected women have a 50% risk of transmitting the mutant IKBKG allele at conception; however, most affected male conceptuses miscarry. Thus, the expected ratio for liveborn children is 33% unaffected females, 33% affected females, and 33% unaffected males. Genetic counseling and prenatal testing is available.

In females, the cells expressing the mutated IKBKG gene due to lyonization selectively die around the time of birth so the X-inactivation is extremely skewed.^[2]

History

This disorder was first reported by Bruno Bloch, a German dermatologist in 1926 and Marion Sulzberger, an American dermatologist in 1928.

References

↑ ^1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 ^1.6 ^1.7 "Dermatology Atlas".
↑ Smahi A, Courtois G, Vabres P; et al. (2000). "Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium". Nature. 405 (6785): 466–72. doi:10.1038/35013114. PMID 10839543.

External links

Template:Congenital malformations and deformations of integument Template:Phakomatoses and other congenital malformations not elsewhere classified

de:Bloch-Sulzberger-Syndrom nl:Incontinentia pigmenti

Template:Jb1

Template:WikiDoc Sources

[Dermatology_Atlas-1] 1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 ^1.6 ^1.7 "Dermatology Atlas".

[2] Smahi A, Courtois G, Vabres P; et al. (2000). "Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium". Nature. 405 (6785): 466–72. doi:10.1038/35013114. PMID 10839543.

[1]

[2]